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Abstract
Background: To estimate the prevalence of respiratory symptoms in individuals with type 2 diabetes, as compared
to the general population.
Methods: Between 2007 and 2010 the screening questionnaire of GEIRD (Gene Environment Interactions in
Respiratory Diseases) study was administered to two samples of Verona general population, aged respectively
45-64 years and 65-84 years, and to a convenience sample of individuals with type 2 diabetes, consequently
recruited at the local Diabetes Centre. Ninety-four and 165 people with type 2 diabetes, aged respectively
45-64 and 65-84 years, were compared with 676 and 591 subjects in the same age range from the general
population. The influence of type 2 diabetes on respiratory symptoms was evaluated by logistic regression
models, controlling for sex, age (45-54, 55-64, 65-74, 75-84 years), education level, smoking habits and heavy vehicle
traffic exposure and adjusting standard errors of ORs for intra-sample correlation.
Results: Compared to the general population, dyspnoea limiting walking pace on level ground (grade 2 dyspnoea) was
more frequently reported by people with type 2 diabetes, irrespective of age (p < 0.001), while self-reported chronic
cough/phlegm was more common in those aged 45-64 years (p = 0.02). These results were confirmed by multivariable
analysis: compared to their counterparts from the general population, people with type 2 diabetes aged 45-54 years
showed an increased risk of reporting grade 2 dyspnoea (OR = 3.92, 95% CI 3.28-4.68) or chronic cough/phlegm
(OR = 1.69, 1.60-1.78). Similar figures held significant at older ages (75-84 years), although partially blunted
(dyspnoea: OR = 1.79, 1.68-1.91; chough/phlegm: OR = 1.09, 1.03-1.16). As such, the interaction between age
class and type 2 diabetes was significant for both respiratory disorders. The proportion of self-reported dyspnoea
among individuals with type 2 diabetes significantly increased across incremental body-mass index (BMI), from
15.4 to 25.4% and further to 41.3% respectively in normoweight, overweight and obese patients (p = 0.048).
Conclusions: People with type 2 diabetes more frequently reported grade 2 dyspnoea and chronic cough/
phlegm than the general population of the same age, although presenting similar smoking habits. Diabetes
appears to anticipate the lung ageing process, recorded in the general population. The increased occurrence
of dyspnoea at incremental BMI among individuals with type 2 diabetes may reflect both cardiovascular and
respiratory impairment in this high-risk patient population.
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Background
Both diabetes and respiratory disorders are highly preva-
lent in elderly subjects [1, 2] and often coexist in the
same subjects. Almost one-half of patients with chronic
bronchitis or chronic obstructive pulmonary disease
(COPD) have coexisting metabolic syndrome [3, 4] and
about 20% have diabetes [5]. COPD has been suggested
to be a risk factor for diabetes [6, 7], but also the reverse
has been reported [8]. As these two conditions both
present low-grade chronic inflammation [9], they have
been recently enclosed in a common general entity, also
referred to as “chronic systemic inflammatory syndrome”
[10]. In addition, disturbances of glucose metabolism
have been found in asthmatic patients [11].
Metabolic syndrome and diabetes are associated with a
modest, albeit statistically significant, impairment of pul-
monary function in a restrictive pattern [2, 12–14]; how-
ever, it is currently still under debate whether and to
what extent the prevalence of respiratory symptoms dif-
fers between individuals with and without diabetes.
Therefore, the present study aimed at investigating the
prevalence of respiratory symptoms in subjects with type
2 diabetes, as compared to the general population.
Methods
Studied samples
In the frame of the GEIRD (Gene Environment Interac-
tions in Respiratory Diseases) study [15] two samples
aged respectively 45-64 and 65-84 years, each compris-
ing 1000 subjects and with a male to female ratio of one,
were randomly selected from the general population of
Verona, using local health authority registry. Between
2007 and 2010 both samples were administered the
GEIRD screening questionnaire, achieving a response
percentage of 70.1% (676/965) and 60.7% (591/973) re-
spectively (after excluding subjects who had died or
moved). Between July 2009 and September 2010 the
same questionnaire was given to a convenience sample
of outpatients with type 2 diabetes, consequently re-
cruited in the local Diabetes Centre (response percent-
age = 95.7%). Ninety-four and 165 outpatients with
diabetes, aged respectively 45-64 and 65-84 years, were
compared with 676 and 591 subjects in the same age
range from the general population.
Assessment of respiratory disorders
The screening questionnaire used to assess respiratory
health was a modified version of the ECRHS (European
Community Respiratory Health Survey) questionnaire
[16], enquiring about socio-demographic characteristics,
education level, smoking habits, outdoor exposure, re-
spiratory symptoms, history of asthma, rhinitis, chronic
bronchitis and eczema, and life impairment (GEIRD
2010; available at www.geird.org) [15].
Subjects were classified as having “current asthma” if
they reported asthma attacks during the last 12 months
or currently taking medicines for asthma, “ever asthma”
if they reported the disease during the lifespan. Allergic
rhinitis and eczema were defined respectively by a posi-
tive answer to the questions “Do you have any nasal al-
lergies including hay fever?” or “Have you ever had
atopic dermatitis or eczema, confirmed by a doctor?”.
Chronic bronchitis was assumed if the subject answered
affirmatively to the question “Have you had cough and
phlegm on most days for a minimum of three months a
year and for at least two successive years?”.
Self-reported doctor-diagnosed asthma or COPD were
also considered, defined respectively by a positive answer
to the questions “Was asthma diagnosed by a doctor?”
or “Have you ever been told by a doctor that you have or
had chronic bronchitis, chronic obstructive pulmonary
disease (COPD) or emphysema? ”.
Modified Medical Research Council (mMRC) grade2
dyspnoea was assumed when the subject reported to
“walk slower than contemporaries on level ground be-
cause of breathlessness”, or to “stop for breath when
walking at own pace”.
Assessment of exposures
With regard to the smoking habits, subjects were classi-
fied as follows: 1) current smokers, if they reported to
have smoked at least one cigarette per day or one cigar
per week for 1 year, and also during the last month; 2)
ex-smokers, if they had smoked at least one cigarette per
day or one cigar per week for 1 year, but not in the last
month; 3) never smokers, otherwise. A previous study
conducted in Verona identified a good agreement
(Cohen’s k = 0.93) between self-reported smoking beha-
vior and serum cotinine levels in participants to the
ECRHS I [17].
Heavy vehicle traffic exposure was assessed by the
question “How often do heavy vehicles (e.g. trucks/buses)
pass your house ?”, whose possible answers were “never/
seldom/ frequently/ constantly”. In Italian participants to
the ECRHS II, a good relation was found between self-
reported level of heavy vehicle traffic exposure and NO2
outdoor concentration, measured by passive sampling
tubes outside participants’ homes [18].
Assessment of body-mass index and glycated
haemoglobin
Information on body-mass index (BMI) and glycated
haemoglobin (HbA1c) was available, respectively, in 146
(56.4%) and 179 (69.1%) individuals with type 2 diabetes.
BMI was calculated by objectively measuring height
(with a Harpenden stadiometer) and weight (with a
properly calibrated scale), and by dividing weight in kilo-
grams by the square of height in metres. A venous blood
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sample was drawn in the morning after an overnight
fast. Haemoglobin A1c was measured by a high-
performance liquid chromatography analyzer (Bio-Rad
Diamat, Milan, Italy); the upper limit of normal for the
laboratory was 5.8%.
Patients were classified according to BMI categories as
normoweight (BMI <25 Kg/m2), overweight (25-29 Kg/m2)
or obese (BMI ≥30 Kg/m2). Un-satisfactory glycaemic
control was considered at HbA1c ≥7% and patients were
classified accordingly in two categories (satisfactory vs. sub-
optimal glycaemic control).
Statistical analyses
Significance of differences between individuals with type
2 diabetes and the general population samples of the
same age was evaluated by Fisher’s exact test for categor-
ical variables, by chi-square test for trend for ordinal var-
iables and by Wilcoxon-Mann-Whitney non-parametric
test for continuous variables.
Significant differences in respiratory symptoms, de-
tected in univariable analysis, were verified in multivari-
able analysis. The latter was accomplished by logistic
regression models, where respiratory symptoms, taken
one at a time, were the response variable, diabetes the
explanatory variable, and sex, age (45-54 (reference), 55-
64, 65-74, 75-84 years), education level (primary school
(reference)/ secondary school/ high school or University),
smoking habits (never (reference)/ past/ current smoker)
and heavy vehicle traffic exposure (constantly/frequently
exposed vs. seldom/never exposed) the potential con-
founders. Standard errors of ORs were adjusted for intra-
sample correlation.
In people with type 2 diabetes, statistical significance of
the influence of BMI (normoweight/ overweight/ obese) or
HbA1c (satisfactory/ sub-optimal) on respiratory symptoms
was evaluated by Fisher’s exact test, and when the
association was significant in univariable analysis, a further
evaluation was accomplished by a logistic regression model,
controlling for sex, age (65-84 vs. 45-64 years), smoking
habits (past/current vs. never smoker).
Results
The demographic characteristics, education level, smok-
ing habits and traffic exposure of the samples under
studies are shown in Table 1. People with type 2 diabetes
had a lower proportion of women than the general
population in the age range 45-64 years. Individuals with
diabetes of all ages had attained a lower education level
and were more exposed to heavy vehicle traffic than
their coevals from the general population. Smoking
habits did not significantly differ between people with
type 2 diabetes and the general population, although the
former presented a slightly higher proportion of ex-
smokers.
Individuals with diabetes of all ages more frequently re-
ported dyspnoea limiting walking pace (modified MRC
grade 2 dyspnoea) than their coevals (p < 0.001) (Table 2).
Compared to the general population, self-reported chronic
cough/phlegm was more common among individuals with
diabetes aged 45-64 years (p = 0.017), while self-reported
eczema tended to be more common, although not signifi-
cantly, among those aged 65-84 years (p = 0.087).
Significant differences recorded in univariate analysis
were verified in multivariable analysis, where a remar-
kable difference was detected in age-related pattern of
respiratory disorders between the general population
and people with type 2 diabetes. In the general popula-
tion, the risk of reporting chronic cough/phlegm (Fig. 1)
or mMRC grade 2 dyspnoea (Fig. 2) increased three-fold
from 45- 54 years to 75-84 years. Among people with
type 2 diabetes the risk of these respiratory disorders
was particularly high in the younger age classes, but the
increasing trend across incremental age categories was
less pronounced. As a consequence, individuals with dia-
betes presented a greater risk of respiratory disorders
than the general population in the younger age classes,
while the difference tended to fade with ageing. With re-
spect to the general population, the OR of mMRC grade
2 dyspnoea among individuals with diabetes was nearly
four (3.92, 95% CI 3.28-4.68; p < 0.001) in the age class
45-54 years, and decreased to 1.79 (1.68-1.91; p < 0.001)
in the age class 75-84 years (Fig. 2). Similarly, the ORs
of chronic chough/phlegm decreased from 1.69 (1.60-
1.78; p < 0.001) to 1.09 (1.03-1.16; p = 0.006) across the
same age ranges (Fig. 1). As a consequence, the inter-
action between age class and diabetes was significant for
both respiratory disorders.
With regard to the other variables included in the
model, constant/frequent exposure to heavy vehicle traf-
fic was associated with a significant increase in the risk
of both chronic cough/phlegm (OR = 2.15, 1.85-2.48;
p < 0.001) and mMRC grade 2 dyspnoea (OR = 1.67,
1.36 – 2.06; p < 0.001), with respect to absent/rare ex-
posure. Moreover, chronic cough/phlegm was more fre-
quently reported by past smokers (OR = 1.47, 1.09-1.97;
p = 0.011) and current smokers (OR = 3.09, 2.23-4.30;
p < 0.001), as compared to never smokers, while mMRC
grade 2 dyspnoea was more frequently reported by
women (OR = 2.02, 1.14–3.59; p = 0.016) with respect
to men.
Most subjects with diabetes were overweight (48%) or
obese (33%) and more than a half (61%) did not achieve
a satisfactory glycemic control, having HbA1c ≥7%.
Median BMI was 28.0 Kg/m2 (interquartile range 25.5-
32.0) and median HbA1c was 7.25% (6.4-8.3). Of note,
the proportion of self-reported dyspnoea among people
with diabetes increased across incremental BMI categor-
ies from 15.4 to 25.4% and further to 41.3%, respectively,
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in normoweight, overweight and obese outpatients
(p = 0.048). When controlling for sex, age, smoking
habits by a logistic regression model, the resulting OR of
grade 2 dyspnoea was 2.07 (0.58-7.38; p = 0.262) in over-
weight patients with type 2 diabetes and 4.51 (1.22-
16.70; p = 0.024) in obese patients, with respect to
normoweight patients. Glycated haemoglobin was sig-
nificantly associated with eczema: patients with HbA1c
<7% more frequently reported eczema than the other pa-
tients (28% vs. 12%; p = 0.013), and in the multivariable
logistic model they presented an OR of self-reported ec-
zema of 3.2 (1.3-8.1; p = 0.013) with respect to patients
with HbA1c ≥7%. No other significant association
between BMI or HbA1c and respiratory disorders in in-
dividuals with type 2 diabetes was detected.
Discussion
The main results of the present study are:
First, individuals with type 2 diabetes more frequently
reported chronic cough and phlegm, and grade 2 dyspnoea
Table 2 Prevalence of respiratory disorders in the study samples
45-64 years 65-84 years
General population Diabetic patients p value General population Diabetic patients p value
(n = 676) (n = 94) (n = 591) (n = 165)
Ever asthma (%) 58 (8.8) 9 (9.7) 0.702 42 (7.5) 10 (6.2) 0.730
Current asthma (%) 39 (5.8) 6 (6.5) 0.814 25 (4.4) 8 (4.9) 0.830
Diagnosed asthma (%) 43 (6.6) 6 (6.7) 1.00 27 (4.9) 5 (3.1) 0.513
Allergic rhinitis (%) 125 (18.7) 15 (16.5) 0.668 75 (13) 24 (15.1) 0.513
Eczema (%) 89 (13.6) 14 (15.6) 0.626 70 (12.8) 28 (18.3) 0.087
Chronic cough/phlegm (%) 108 (16.7) 24 (27.6) 0.017 134 (24.6) 41 (27.9) 0.454
Diagnosed COPD (%) 41 (6.2) 7 (7.9) 0.496 78 (14.0) 18 (11.8) 0.593
mMCR grade2 dyspnoea (%) 52 (7.9) 20 (23) <0.001 77 (13.7) 47 (30.9) <0.001
P values were computed by Fisher’s exact test. Significant results are highlighted in bold
Table 1 Demographic characteristics, education level and exposure to smoking or heavy vehicle traffic in the study samples
45-64 years 65-84 years
General population Diabetic patients p value General population Diabetic patients p value
(n = 676) (n = 94) (n = 591) (n = 165)
Female (%) 360 (53.3) 37 (39.4) 0.015 261 (44.2) 66 (40.2) 0.375
Age (mean ± SD) 55.3 (± 5.8) 56.1 (± 5.8) z = −1.30, p = 0.193 73.3 (± 5.5) 73.2 (± 5.5) z = 0.20, p = 0.842
Education level (%) z = −4.73,
p < 0.001
z = −6.58,
p < 0.001
Primary school 86 (15.6) 29 (31.5) 258 (44.2) 119 (74.8)
Secondary school 186 (33.6) 36 (39.1) 162 (27.7) 24 (15.1)
High school 192 (34.7) 24 (26.1) 120 (20.5) 15 (9.4)
University 89 (16.1) 3 (3.3) 44 (7.5) 1 (0.6)
Smoking habits (%) 0.418 0.560
Never-smokers 278 (42.1) 31 (34.8) 330 (57.8) 85 (55.6)
Ex-smokers 228 (34.6) 35 (39.3) 185 (32.4) 56 (36.6)
Current smokers 154 (23.3) 23 (25.8) 56 (9.8) 12 (7.8)
Heavy vehicle traffic
exposure
z = −2.51,
p = 0.012
z = −6.43,
p < 0.001
Never 121 (22.1) 18 (20.2) 144 (25.1) 15 (9.3)
Seldom 236 (43.1) 32 (36.0) 227 (39.6) 59 (36.4)
Frequently 113 (20.7) 11 (12.4) 128 (22.3) 30 (18.5)
Constantly 77 (14.1) 28 (31.5) 74 (12.9) 58 (35.8)
P values were computed by Fisher’s exact test for sex and smoking habits, chi-square test for trend for education and exposure to heavy vehicle traffic
and Wilcoxon-Mann-Whitney non-parametric test for age. Significant results are highlighted in bold
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as compared to the general population of the same
age, although presenting similar smoking habits. These
differences tended to decrease at older ages, thus sug-
gesting that diabetes induces an accelerating ageing of
the lung.
Second, grade 2 dyspnoea was most often reported by
obese outpatients with type 2 diabetes.
Third, the prevalence of asthma or allergic rhinitis was
not significantly associated with diabetes. Eczema tended
to be more prevalent in individuals with type 2 diabetes
within the age range 65-84 years, although the associ-
ation was not statistically significant.
The most remarkable finding of the present study was a
three-to-four fold increase in dyspnoea observed in indi-
viduals with type 2 diabetes with respect to the general
population. Accordingly, available literature supports the
notion that the lung is a target organ for diabetic injury
[19] and that type 2 diabetes is associated with reduced
lung volumes and airflow limitation [20]. Usually, a pat-
tern of modest lung restriction and reduced diffusion cap-
acity has been described in individuals with type 2
diabetes [13, 14, 21, 22]. However, some studies have also
linked obstructive diseases, in particular COPD, to meta-
bolic syndrome or impaired glucose tolerance [10, 23].
In the present study, the prevalence of diagnosed
COPD did not differ between individuals with type 2
diabetes and coevals from the general population. How-
ever, chronic cough/phlegm, which was once considered
the first stage of the disease (GOLD stage 0) [24], was
more commonly reported by people with diabetes.
Although dyspnoea is the distinctive hallmark of most
respiratory diseases, obesity or impairment of the cardio-
vascular system may be responsible for the increased
prevalence of dyspnoea among individuals with type 2
diabetes. However, impairment of both cardiovascular
and respiratory systems may frequently coexist in the
same subject. The recent ECLIPSE epidemiological study
found that diabetes was associated with higher MRC
dyspnoea scores and reduced 6-min walk distance and
that comorbidities of heart disease and diabetes corre-
lated with increased systemic inflammation [25].
Individuals with type 2 diabetes self-reported a higher
level of exposure to heavy vehicle traffic than the general
population, and this difference could partly explain the
higher prevalence of dyspnoea and chronic cough/
phlegm among people with type 2 diabetes. However,
the association between type 2 diabetes and respiratory
disorders persisted even after controlling for traffic ex-
posure in a multivariable model.
In the present study an increased prevalence of eczema
was observed among older individuals with type 2 dia-
betes. However, although an association between diabetes
and eczema was expected on the basis of current litera-
ture, this figure did not reach significance, possibly due to
limited statistical power. Indeed, topical steroids are often
used for long-term control of eczema despite contraindi-
cations, and this could not only worsen eczema, but also
elicit insulin resistance. An altered glucose metabolism
occurs in nearly half of glucocorticoid-treated patients,
even after treatment reduction or withdrawal [26]. More-
over, a larger amount of steroid could be absorbed during
topic treatment in elderly individuals, due to reduced skin
thickness [27]. Alternately, insulin resistance status could
induce eczema, by decreasing the expression of Δ-6-
desaturase [28], an hepatic enzyme involved in the synthe-
sis of gamma-linolenic acid, whose levels are reduced in
atopic eczema [29].
Asthma-like symptoms have been reported to be more
frequent in adults with metabolic syndrome [30] or with
Fig. 1 Odds ratios (ORs) of reporting chronic cough/phlegm in the
general population (blue columns) and in individuals with type 2
diabetes (red columns) as a function of age class. Columns are ORs,
bars are 95% confidence intervals. ORs were computed by a logistic
regression model, controlling for sex, age, education level, smoking
habits and exposure to heavy vehicle traffic
Fig. 2 Odds ratios (ORs) of reporting mMRC grade 2 dyspnoea in
the general population (blue columns) and in individuals with type 2
diabetes (red columns) as a function of age class. Columns are ORs,
bars are 95% confidence intervals. ORs were computed by a logistic
regression model, controlling for sex, age, education level, smoking
habits and exposure to heavy vehicle traffic
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insulin resistance, a basic alteration of type 2 diabetes
[31]. Other authors have argued that insulin itself may
increase the contractility of airway smooth muscle cells,
thus contributing to bronchial hyper-responsiveness
[21]. However, these findings were not supported by the
present research, as the prevalence of diagnosed or self-
reported asthma was similar in both individuals with
type 2 diabetes and in the general population.
Pathophysiologic mechanisms
Hyperglycemia could trigger inflammatory response,
thus leading to structural modification of pulmonary tis-
sue and impaired lung function [9]. Moreover, lung
function volumes have been shown to be inversely asso-
ciated with insulin resistance [31].
On the other hand, it could be also hypothesized that
diabetes can worsen or even accelerate the derangement
of respiratory function by inducing structural alterations
[9, 32]. In fact, the pulmonary alveolar-capillary network is
a large microvascular unit that may also be affected by
diabetic microangiopathy [33]. Human autopsy studies in
subjects with diabetes have observed cell proliferation
with hypertrophy of interstitial matrix, increased thickness
of the bronchial, alveolar and capillary basement mem-
branes and an accompanying collapse of the alveolar space
[34]. In this regard, a recent study reported a significant
reduction of carbon monoxide diffusing capacity in indi-
viduals with diabetes, as compared to their counterparts
without diabetes [35]. This structural alteration may also
be related to the increased risk of individuals with diabetes
to be hospitalized for pneumonia [35, 36].
Strengths and limitations
A strength of this study was the use of a standardized
internationally-validated questionnaire to assess respira-
tory health. In addition, when assessing the impact of
diabetes on respiratory symptoms, samples from the
general population of the same age were considered as
reference.
Smoking is the main risk factor for respiratory diseases
in the Western world, being responsible for up to 80-90%
of COPD cases [37], but it also enhances the risk of devel-
oping type 2 diabetes [38–40]. Hence, smoking status may
act as a confounder of the relation between diabetes and
respiratory health. However, in the present study smoking
habits were not significantly different between individuals
with type 2 diabetes and their counterparts from the gen-
eral population. Moreover, multivariable analysis was ad-
justed for self-reported smoking history, as well as for
heavy vehicle traffic exposure.
However, some limitations should also be acknow-
ledged. First, information on respiratory health was
collected by a self-administered questionnaire without dir-
ect assessment of respiratory function. Second, response
percentage was higher among individuals with type 2
diabetes (95.7%) than in the general population samples
(70.1 and 60.7%, respectively, in people aged 45-64 and
65-84 years). As people with respiratory disorders tend
to be early responders to self-administered question-
naires [41], a reduction in response percentage may
have led to overestimate the prevalence of respiratory
symptoms in the general population, thus partly mas-
king the difference between individuals with type 2 dia-
betes and the general population. Third, the prevalence
of type 2 diabetes can be expected to be around 10% in
the general Italian population aged 45-84 years [1, 42].
However, individuals with diabetes could not be ex-
cluded from general population samples, as the GEIRD
screening questionnaire did not enquire about this dis-
ease. This probably could have also led to underesti-
mate differences in respiratory disorders between
subjects with diabetes and the general population. Fi-
nally, the cross-sectional design of the present study
does allow to detect associations, such as between
respiratory disorders and type 2 diabetes, but not to
infer the causal relation involved.
Conclusions
In conclusion, our data confirmed the evidence of an in-
creased prevalence of respiratory symptoms (dyspnoea,
chronic cough/phlegm) in individuals with type 2 diabetes,
when compared to the general population of the same
age. This difference was larger in the age range 45-64 years
than at older ages, thus suggesting that diabetes may an-
ticipate the lung ageing process. Therefore, our results
may be relevant to the practicing physicians as they high-
light the potential clinical utility of an early screening for
respiratory diseases in individuals with type 2 diabetes.
When deemed necessary, the prompt initiation of specific
treatments for respiratory diseases would be advisable by
comprehensively accounting for the accompanying multi-
morbidities and modifiable risk factors.
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